ClinicalTrials.gg
TerminatedNCT04428333INDUCE-4Updated Oct 9, 2024Results posted

Study of GSK3359609 With Pembrolizumab and 5-fluorouracil (5-FU)-Platinum Chemotherapy in Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

A Phase 3 interventional study of Feladilimab and Pembrolizumab in Neoplasms, Head and Neck, sponsored by GlaxoSmithKline. Terminated at 71 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-10-09.

Primary conditionSquamous Cell Carcinoma of Head and NeckRegistry: Head and Neck NeoplasmsReclassifiedWhy we changed it
Registry
Head and Neck Neoplasms — the first condition term the registry derived for this study.
ClinicalTrials.gg
Squamous Cell Carcinoma of Head and Neck
Why
  1. The study's title name Squamous Cell Carcinoma of Head and Neck, a narrower term within Head and Neck Neoplasms.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Treatment

Why this study was terminated
The trial was stopped by the sponsor based on assessment of the clinical data

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
117
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 164 studies in Squamous Cell Carcinoma of Head and Neck with a site in Canada — 30 open to participants now, 57 under way, 13 of them phase 3. Squamous Cell Carcinoma of Head and Neck · Canada.

Enrollment
80th of 149
117 · median 129
Started
2020
with 15 others
Phase 3
33 of 164
5 open now
Registered
106th of 164
by date
Lead sponsor
6 of 164
GlaxoSmithKline

Among the 164 studies in Squamous Cell Carcinoma of Head and Neck with a site in Canada, this one is the 80th largest by enrollment of the 149 interventional ones that give a count, is one of 16 that started in 2020, is one of 33 in phase 3, and was the 106th registered.

Squamous Cell Carcinoma of Head and Neck

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Open to participants now

30 of the 164 studies in Squamous Cell Carcinoma of Head and Neck with a site in Canada are open now. Recruiting first, the newest first:

25 more — sign in →

All 30 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 435 Squamous Cell Carcinoma of Head and Neck studies recruiting now, 311 (71%) set no upper age limit and 87 (20%) stop at 75 or younger; 5 take children under 18; 13 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 164 studies in Squamous Cell Carcinoma of Head and Neck with a site in Canada, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate if the addition of GSK3359609 to pembrolizumab in combination with 5FU-platinum based chemotherapy improves the efficacy of the pembrolizumab combination with 5FU-platinum based chemotherapy in participants with recurrent or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC). This randomized, double-blinded, Phase II/III study will compare the combination of GSK3359609 with pembrolizumab and 5FU-platinum chemotherapy to placebo in combination with pembrolizumab and 5FU-platinum chemotherapy in participants with recurrent or metastatic HNSCC of the oral cavity, oropharynx, hypopharynx or larynx.

03

Conditions studied

  • Neoplasms, Head and Neck

Browse trials for

Keywords

  • GSK3359609
  • Pembrolizumab
  • Programmed cell death receptor 1
  • Inducible T cell co-stimulatory receptor
  • Keynote-A02
  • Phase II/III
  • Platinum-based chemotherapy
  • 5FU
  • Head and neck squamous cell carcinoma
04

In context

Squamous Cell Carcinoma of Head and Neck Reclassified

2,019 studies on the registry are indexed under Squamous Cell Carcinoma of Head and Neck; 573 are open to participants now.

This study's enrollment of 117 is above the median of 48 across 1,653 interventional studies indexed under Squamous Cell Carcinoma of Head and Neck.

Browse Squamous Cell Carcinoma of Head and Neck studies →

Lead sponsor

GlaxoSmithKline is the lead sponsor of 3,650 studies on the registry; 117 are open to participants now.

Of its 265 completed or terminated interventional studies of FDA-regulated products, 241 (91%) have results posted.

Compared within Squamous Cell Carcinoma of Head and Neck, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Head and Neck Neoplasms. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Capable of giving signed
  • Male or female, age >=18 years
  • HNSCC that was diagnosed as recurrent or and considered incurable by local therapies.
  • Primary tumor location of the oral cavity, oropharynx, hypopharynx or larynx.
  • No prior systemic therapy administered in the recurrent or metastatic setting (with the exception of systemic therapy completed >6 months prior if given as part of multimodal treatment for locally advanced disease and no disease progression/recurrence within 6 months of the completion of curatively intended systemic treatment).
  • per version 1.1 guidelines
  • (ECOG) Performance Status (PS) score of 0 or 1.
  • Adequate organ function.
  • of at least 12 weeks.
  • Female participants: must not be pregnant, not breastfeeding, and be either not a woman of (WOCBP); or be a WOCBP who agrees to use a highly effective method of from 30 days prior to randomization and for at least 120 days after the last dose of study treatment.
  • Male participants with female partners of child-bearing potential: must agree to use a highly effective contraception while receiving study treatment and for at least 120 days after the last dose of study treatment and refrain from donating sperm during this periods.
  • Provide tumor tissue from excisional or core (fine needle aspirates and bone biopsies are not acceptable) acquired within 2 years prior to randomization for immunohistochemistry (IHC) testing by central laboratory.
  • Have PD-L1 IHC CPS status by central laboratory testing.
  • Have results from testing of human papilloma virus (HPV) status for oropharyngeal cancer.

Exclusion criteria

Exclusion Criteria:

  • Prior therapy with an /L1/L2, anti-Inducible T Cell Co-Stimulatory Receptor (ICOS) directed agent.
  • Systemic approved or anticancer therapy within 30 days or 5 half lives of the drug, whichever is shorter. At least 14 days must have elapsed between the last dose of prior anticancer agent and the date of randomization. - Has high risk of bleeding (examples include but not limited to tumors encasing or infiltrating a major vessel [i.e. carotid, jugular, bronchial artery] and/or exhibits other high-risk features such as an arteriovenous fistula)
  • Active tumor bleeding - Grade 3 or Grade 4 hypercalcemia.
  • Major surgery less than or equal to (\<=) 28 days prior to randomization.
  • Participants must have also fully recovered from any surgery (major or minor) and/or its complications before randomization
  • Toxicity from previous anticancer treatment that includes: a. Grade 3/Grade 4 toxicity considered related to prior immunotherapy and that led to treatment discontinuation and b. toxicity related to prior treatment that has not resolved to \<=Grade 1 (except alopecia, hearing loss, endocrinopathy managed with replacement therapy, and peripheral neuropathy which must be \<=Grade 2).
  • Received transfusion of blood products or administration of colony stimulating factors within 14 days prior to randomization.
  • Central nervous system (CNS) , with the following exception: Participants with asymptomatic who are clinically stable and have no requirement for for at least 14 days prior to randomization.
  • Invasive or history of invasive malignancy other than disease under study within the last 3 years with the exception of: a. any other invasive malignancy for which the participant was definitively treated, has been disease-free for \<=3 years. b. curatively treated non-melanoma skin cancer or successfully treated in situ carcinoma and/or. c. low-risk early stage prostate cancer defined as: Stage T1c or T2a with a Gleason score \<=6 and prostatic-specific antigen less than (\<)10 nanograms per milliliter (ng/mL) either treated with definitive intent or untreated in active surveillance that has been stable for the past year prior to randomization.
  • disease or syndrome that required systemic treatment within the past 2 years.
  • Has a diagnosis of immunodeficiency or is receiving systemic steroids (>10 milligram [mg] oral prednisone or equivalent) or other agents within 7 days prior to randomization.
  • Receipt of any within 30 days prior randomization.
  • Prior allogeneic/autologous bone marrow or solid organ transplantation.
  • Has current pneumonitis or history of non-infectious pneumonitis that required steroids or other immunosuppressive agents.
  • Recent history (within the past 6 months) of uncontrolled symptomatic ascites, pleural or pericardial effusions.
  • Recent history (within the past 6 months) of gastrointestinal obstruction that required surgery, acute diverticulitis, inflammatory bowel disease, or intra-abdominal abscess.
  • Recent history of allergen desensitization therapy within 4 weeks of randomization.
  • History or evidence of cardiac abnormalities within the 6 months prior to randomization which include: a. Serious, uncontrolled cardiac arrhythmia or abnormalities including second degree (Type II) or third-degree atrioventricular block. b. Cardiomyopathy, myocardial infarction, acute coronary syndromes(including unstable angina pectoris), coronary angioplasty, stenting or bypass grafting. c. Congestive heart failure (Class II, III, or IV) as defined by the functional classification system. d. Symptomatic pericarditis.
  • Current unstable liver or biliary disease per investigator assessment defined by the presence of ascites, encephalopathy, coagulopathy, hypoalbuminemia, esophageal or gastric varices, persistent jaundice, or cirrhosis.
  • Active infection requiring systemic therapy.
  • Known (HIV) infection, or positive test for active infection (presence of hepatitis B surface antigen), or active infection.
  • History of severe to monoclonal antibodies or to the chemotherapies under investigation including any ingredient used in the formulation.
  • Known history of active tuberculosis.
  • Any serious (>=Grade 3) and/or unstable pre-existing medical condition (aside from malignancy).
  • Any psychiatric disorder, or other condition that could interfere with participant's safety, obtaining , or compliance to the study procedures in the opinion of the investigator.
  • Is currently participating in or has participated in a study of an investigational agent or has used an investigational device within 4 weeks prior to the date of randomization.
Terms in these criteria, in plain language(24)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

06

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
117 participants (actual)

Study arms

  • Experimental
    Feladilimab + Pembrolizumab + 5-FU-platinum chemotherapy

    Drug: Feladilimab · Drug: Pembrolizumab · Drug: Platinum based chemotherapy · Drug: Fluorouracil (5FU)

  • Placebo comparator
    Placebo + Pembrolizumab + 5-FU-platinum chemotherapy

    Drug: Pembrolizumab · Drug: Placebo · Drug: Platinum based chemotherapy · Drug: Fluorouracil (5FU)

Interventions

  • Humanized anti-inducible T cell co-stimulatory receptor (ICOS) immunoglobulin G4 (IgG4) monoclonal antibody (mAb)

  • Humanized anti- programmed cell death receptor1 (anti-PD-1) IgG4 mAb

  • DrugPlacebo

    Sterile normal saline

  • DrugPlatinum based chemotherapy

    Cisplatin/carboplatin

  • 5-fluorouracil

07

What researchers measure

Primary outcomes

  1. Overall Survival (OS) in mITT Population

    OS was defined as the time from the date of randomization to the date of death due to any cause. Kaplan-Meier estimate for the median OS is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.

    Time frame: Up to approximately 7 months

  2. OS in Programmed Death Receptor-ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 Population

    OS was defined as the time from the date of randomization until the date of death due to any cause. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells. Kaplan-Meier estimate for the median OS is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.

    Time frame: Up to approximately 7 months

  3. Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 in mITT Population

    PFS per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 was defined as the time from the date of randomization to the date of first documented disease progression or death due to any cause, whichever occurs first. Kaplan-Meier estimate for the median PFS is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.

    Time frame: Up to approximately 7 months

Secondary outcomes

  1. PFS Per RECIST v1.1 in the PD-L1 CPS ≥1 Population

    PFS per RECIST v1.1 was defined as the time from the date of randomization until the date of disease progression or death due to any cause, whichever occurs first. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells. Kaplan-Meier estimate for the median PFS is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.

    Time frame: Up to approximately 7 months

  2. Milestone OS Rate at 12, 24 and 36 Months in mITT Population

    Milestone OS rate at 12, 24, and 36 months was not evaluated.

    Time frame: Months 12, 24 and 36

  3. Milestone OS Rate at 12, 24 and 36 Months in PD-L1 CPS ≥1 Population

    Milestone OS rate at 12, 24, and 36 months was not evaluated. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

    Time frame: Months 12, 24 and 36

  4. Overall Response Rate (ORR) Per RECIST v1.1 in mITT Population

    ORR per RECIST v1.1 was defined as the proportion of the participants who have a complete response (CR) or partial response (PR) as the best overall response per RECIST v1.1 based upon investigator assessment. As a randomized double-blind study in which primary endpoints are OS and PFS, the confirmation of CR and PR was not required. Rate and associated 2-sided 95 percent Exact (Clopper-Pearson) Confidence Intervals are provided for each treatment arm which are unadjusted.

    Time frame: Up to approximately 7 months

  5. ORR Per RECIST v1.1 in PD-L1 CPS ≥1 Population

    ORR per RECIST v1.1 was defined as the proportion of the participants who have a complete response (CR) or partial response (PR) as the best overall response per RECIST v1.1 based upon investigator assessment. As a randomized double-blind study in which primary endpoints are OS and PFS, the confirmation of CR and PR was not required. Rate and associated 2-sided 95 percent Exact (Clopper-Pearson) Confidence Intervals are provided for each treatment arm which are unadjusted. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

    Time frame: Up to approximately 7 months

  6. Disease Control Rate (DCR) Per RECIST v1.1 in mITT Population

    DCR per RECIST v1.1 based upon investigator assessment, was defined as the percentage of participants with a best overall response of CR or PR at any time plus stable disease (SD) meeting the minimum time of 15 weeks. A status of SD≥15 weeks will be assigned if the follow-up disease assessment has met the SD criteria at least once after the date of randomization at a minimum of 14 weeks (98 days) considering a one-week visit window. Rate and associated 2-sided 95 percent Exact (Clopper-Pearson) Confidence Intervals are provided for each treatment arm which are unadjusted.

    Time frame: Up to approximately 7 months

  7. DCR Per RECIST v1.1 in PD-L1 CPS ≥1 Population

    DCR per RECIST v1.1 based upon investigator assessment, was defined as the percentage of participants with a best overall response of CR or PR at any time plus stable disease (SD) meeting the minimum time of 15 weeks. A status of SD≥15 weeks will be assigned if the follow-up disease assessment has met the SD criteria at least once after the date of randomization at a minimum of 14 weeks (98 days) considering a one-week visit window. Rate and associated 2-sided 95 percent Exact (Clopper-Pearson) Confidence Intervals are provided for each treatment arm which are unadjusted. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

    Time frame: Up to approximately 7 months

  8. Duration of Response (DoR) Per RECIST v1.1 in mITT Population

    DoR per RECIST v1.1 is defined as the time from first documented evidence of CR or PR until first documented disease progression per RECIST v1.1 based upon investigator assessment or death due to any cause, whichever occurs first, among participants who demonstrated CR or PR as the best overall response per RECIST v1.1. Kaplan-Meier estimate for the median DoR is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.

    Time frame: Up to approximately 7 months

  9. DoR Per RECIST v1.1 in PD-L1 CPS ≥1 Population

    DoR per RECIST v1.1 is defined as the time from first documented evidence of CR or PR until first documented disease progression per RECIST v1.1 based upon investigator assessment or death due to any cause, whichever occurs first, among participants who demonstrated CR or PR as the best overall response per RECIST v1.1. Kaplan-Meier estimate for the median DoR is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

    Time frame: Up to approximately 7 months

  10. Number of Participants With Adverse Events (AEs) in Safety Population

    An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention

    Time frame: Up to approximately 37.2 months

  11. Number of Participants With Serious Adverse Events (SAEs) in Safety Population

    SAE was defined as any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect and other situations according to medical or scientific judgement.

    Time frame: Up to approximately 37.2 months

  12. Number of Participants With Adverse Events of Special Interest (AESI) in Safety Population

    AESI were defined as events of potential immunologic etiology, including immune-related AEs (irAEs).

    Time frame: Up to approximately 37.2 months

  13. Number of Participants With AEs in Programmed Death Ligand-1 (PD-L1) Combined Positive Score (CPS ≥1) Population

    Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

    Time frame: Up to approximately 37.2 months

  14. Number of Participants With SAEs in PD-L1 CPS ≥1 Population

    SAE was defined as any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect and other situations according to medical or scientific judgement. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

    Time frame: Up to approximately 37.2 months

  15. Number of Participants With AESIs in PD-L1 CPS ≥1 Population

    AESI were defined as events of potential immunologic etiology, including immune-related AEs (irAEs). CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

    Time frame: Up to approximately 37.2 months

  16. Severity of AEs in Safety Population

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Severity for each AE was reported during the study and assigned a grade according to the NCI-CTCAE v5.0. from Grade 1 through Grade 5. Grade 1= mild toxicity; Grade 2 = moderate toxicity; Grade 3 = severe toxicity; Grade 4 = life-threatening or disabling toxicity, Grade 5 = death related to toxicity.

    Time frame: Up to approximately 37.2 months

  17. Severity of SAEs in Safety Population

    A SAE was defined as any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, is a congenital anomaly/birth defect, any other situation such as important medical events according to medical or scientific judgement. Severity for each SAE was reported during the study and assigned a grade according to the NCI-CTCAE v5.0. from Grade 1 through Grade 5. Grade 1= mild toxicity; Grade 2 = moderate toxicity; Grade 3 = severe toxicity; Grade 4 = life-threatening or disabling toxicity, Grade 5 = death related to toxicity. Data of participants experiencing SAEs of Grade \>= 3 has been presented.

    Time frame: Up to approximately 37.2 months

  18. Severity of AESIs in Safety Population

    AESI were defined as events of potential immunologic etiology, including immune-related AEs (irAEs). Severity of each AESI was reported during the study and was assigned a grade according to the NCI-CTCAE. AESIs severity were graded on a 5-point scale as: 1 = mild; discomfort noticed, but no disruption to daily activity, 2 = moderate; discomfort sufficient to reduce or affect normal daily activity, 3 = severe; inability to work or perform normal daily activity, 4 = life-threatening consequences and 5 = death related to AE. Data of participants experiencing AESIs of Grade \>= 3 have been presented.

    Time frame: Up to approximately 37.2 months

  19. Severity of AEs in PD-L1 CPS ≥1 Population

    An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Severity for each AE was reported during the study and assigned a grade according to the NCI-CTCAE v5.0. from Grade 1 through Grade 5. Grade 1= mild toxicity; Grade 2 = moderate toxicity; Grade 3 = severe toxicity; Grade 4 = life-threatening or disabling toxicity, Grade 5 = death related to toxicity. Data of participants experiencing AEs of Grade \>= 3 have been presented. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

    Time frame: Up to approximately 37.2 months

  20. Severity of SAEs in PD-L1 CPS ≥1 Population

    A SAE was defined as any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, is a congenital anomaly/birth defect, any other situation such as important medical events according to medical or scientific judgement. Severity for each SAE was reported during the study and assigned a grade according to the NCI-CTCAE v5.0. from Grade 1 through Grade 5. Grade 1= mild toxicity; Grade 2 = moderate toxicity; Grade 3 = severe toxicity; Grade 4 = life-threatening or disabling toxicity, Grade 5 = death related to toxicity. Data of participants that experienced SAEs of Grade \>= 3 have been presented. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

    Time frame: Up to approximately 37.2 months

  21. Severity of AESI in PD-L1 CPS ≥1 Population

    AESI were defined as events of potential immunologic etiology, including immune-related AEs (irAEs). Severity of each AESI was reported during the study and was assigned a grade according to the NCI-CTCAE. AESIs severity were graded on a 5-point scale as: 1 = mild; discomfort noticed, but no disruption to daily activity, 2 = moderate; discomfort sufficient to reduce or affect normal daily activity, 3 = severe; inability to work or perform normal daily activity, 4 = life-threatening consequences and 5 = death related to AE. Data of participants that experienced AESIs of Grade \>= 3 have been presented.

    Time frame: Up to approximately 37.2 months

  22. Number of Participants With Dose Modifications in Safety Population

    Number of participants with dose modifications (including dose interruptions, dose delays, dose reductions and treatment discontinuations) were reported by each interventional component.

    Time frame: Up to approximately 7 months

  23. Number of Participants With Dose Modifications in PD-L1 CPS ≥1 Population

    Number of participants with dose modifications (including dose interruptions, dose delays, dose reductions and treatment discontinuations) were reported by each interventional component. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

    Time frame: Up to approximately 7 months

  24. Time to Deterioration (TTD) in Pain in mITT Population

    TTD in pain is defined as the time from randomization to the first definitive meaningful deterioration from baseline in the European Organization for Research and Treatment of Cancer Item Library(EORTC IL51) Questionnaire pain domain, i.e. an increase from baseline of at least 8.33 observed at all subsequent non-missing visits. The EORTC Quality of Life Questionnaire 35-Item Head and Neck Module (QLQ-H\&N35) is a head and neck specific module with multi-item scales. The mouth pain, swallowing, speech problems, opening mouth, coughing, feeding tube, and trouble with social eating domains were administered and referred to as the EORTC IL51. The questionnaire scores for each scale and single-item measure are averaged and transformed linearly to present a score ranging from 0-100. A high score represents a high/healthy level of functioning. Kaplan-Meier estimate for the median TTD is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.

    Time frame: Up to approximately 7 months

  25. TTD in Pain in PD-L1 CPS ≥1 Population

    TTD in pain is defined as the time from randomization to the first definitive meaningful deterioration from baseline in the EORTC IL51 pain domain, i.e. an increase from baseline of at least 8.33 observed at all subsequent non-missing visits. The EORTC QLQ-H\&N35 is a head and neck specific module with multi-item scales. The mouth pain, swallowing, speech problems, opening mouth, coughing, feeding tube, and trouble with social eating domains were administered and referred to as the EORTC IL51. The questionnaire scores for each scale and single-item measure are averaged and transformed linearly to present a score ranging from 0-100. A high score represents a high/healthy level of functioning. Kaplan-Meier estimate for the median TTD is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells to the total number of viable tumor cells.

    Time frame: Up to approximately 7 months

  26. TTD in Physical Function in mITT Population

    TTD in physical function (PF) is defined as the time from randomization to the first definitive meaningful deterioration from baseline in the PF T-score, i.e. a decrease from baseline of at least 2.4 observed at all subsequent non-missing visits, as measured by the Patient-Reported Outcomes Measurement Information System - Physical Function (PROMIS PF 8c).The PROMIS PF 8c is an 8-item fixed length short form derived from the PROMIS Physical Function item bank. It includes a 5-point scale with three sets of response options. Scores on the PROMIS PF 8c are reported on a T score metric (mean = 50 and SD = 10), with higher scores reflecting better physical functioning.

    Time frame: Up to approximately 7 months

  27. TTD in Physical Function in PD-L1 CPS ≥1 Population

    TTD in PF is defined as the time from randomization to the first definitive meaningful deterioration from baseline in the PF T-score, i.e. a decrease from baseline of at least 2.4 observed at all subsequent non-missing visits, as measured by the PROMIS PF 8c.The PROMIS PF 8c is an 8-item fixed length short form derived from the PROMIS Physical Function item bank. It includes a 5-point scale with three sets of response options. Scores on the PROMIS PF 8c are reported on a T score metric (mean = 50 and SD = 10), with higher scores reflecting better physical functioning. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells

    Time frame: Up to approximately 7 months

08

Results

Posted May 25, 2022

Participant flow

Recruitment in the study stopped following the review of unblinded interim safety and efficacy data by IDMC, after a pre-specified futility analysis of the 209229(NCT04128696) trial. A Dear investigator letter (DIL) was issued to stop screening \& randomization of more participants in both studies. Participants discontinued feladilimab/placebo, but treatment with pembrolizumab plus fluorouracil (5FU) platinum chemotherapy continued until disease progression, death or unacceptable toxicity.

Participant flow — Overall Study
MilestoneFeladilimab + Pembrolizumab + 5-FU-platinum ChemotherapyPlacebo + Pembrolizumab + 5-FU-platinum Chemotherapy
Started5760
Modified intent-to-treat (mitt) population5255
Safety population5165
Completed3735
Not completed2025
Withdrew: Physician decision56
Withdrew: Withdrawal by subject13
Withdrew: Study terminated by sponsor1416

Outcome measures

PrimaryOverall Survival (OS) in mITT Population

OS was defined as the time from the date of randomization to the date of death due to any cause. Kaplan-Meier estimate for the median OS is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.

Time frame:
Up to approximately 7 months
Reported as:
Median · Months
Overall Survival (OS) in mITT Population
MonthsFeladilimab + Pembrolizumab + 5-FU-platinum ChemotherapyPlacebo + Pembrolizumab + 5-FU-platinum Chemotherapy
Overall Survival (OS) in mITT PopulationNA (5.1 to NA)NA (4.1 to NA)
Statistical analysis
  • Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy vs Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy · Stratified Cox proportional hazard model · p = 0.740 (Nominal p-value was calculated based on the one sided log-rank test, stratified by stratified by PD-L1 expression (CPS ≥20 vs. 1≤ CPS \<20 vs. CPS \<1) and HPV status (oropharynx HPV positive vs oropharynx HPV negative/unknown and non-oropharynx).) · Hazard ratio (hr): 2.16 · 95% CI 0.20 to 23.87
PrimaryOS in Programmed Death Receptor-ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 Population

OS was defined as the time from the date of randomization until the date of death due to any cause. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells. Kaplan-Meier estimate for the median OS is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.

Time frame:
Up to approximately 7 months
Reported as:
Median · Months
OS in Programmed Death Receptor-ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 Population
MonthsFeladilimab + Pembrolizumab + 5-FU-platinum ChemotherapyPlacebo + Pembrolizumab + 5-FU-platinum Chemotherapy
OS in Programmed Death Receptor-ligand 1 (PD-L1) Combined Positive Score (CPS) ≥1 PopulationNA (5.1 to NA)NA (4.1 to NA)
Statistical analysis
  • Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy vs Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy · Stratified Cox proportional hazard model · p = 0.740 (Nominal p-value was calculated based on the one sided log-rank test, stratified by stratified by PD-L1 expression (CPS ≥20 vs. 1≤ CPS \<20) and HPV status (oropharynx HPV positive vs oropharynx HPV negative/unknown and non-oropharynx).) · Hazard ratio (hr): 2.16 · 95% CI 0.20 to 23.87
PrimaryProgression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 in mITT Population

PFS per Response Evaluation Criteria in Solid Tumors (RECIST) version (v)1.1 was defined as the time from the date of randomization to the date of first documented disease progression or death due to any cause, whichever occurs first. Kaplan-Meier estimate for the median PFS is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.

Time frame:
Up to approximately 7 months
Reported as:
Median · Months
Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 in mITT Population
MonthsFeladilimab + Pembrolizumab + 5-FU-platinum ChemotherapyPlacebo + Pembrolizumab + 5-FU-platinum Chemotherapy
Progression-free Survival (PFS) Per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v)1.1 in mITT Population5.5 (3.7 to 5.5)4.7 (4.7 to 5.6)
Statistical analysis
  • Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy vs Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy · Stratified Cox proportional hazard model · p = 0.284 (Nominal p-value was calculated based on the one sided log-rank test, stratified by stratified by PD-L1 expression (CPS ≥20 vs. 1≤ CPS \<20 vs. CPS \<1) and HPV status (oropharynx HPV positive vs oropharynx HPV negative/unknown and non-oropharynx).) · Hazard ratio (hr): 0.70 · 95% CI 0.20 to 2.43
SecondaryPFS Per RECIST v1.1 in the PD-L1 CPS ≥1 Population

PFS per RECIST v1.1 was defined as the time from the date of randomization until the date of disease progression or death due to any cause, whichever occurs first. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells. Kaplan-Meier estimate for the median PFS is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.

Time frame:
Up to approximately 7 months
Reported as:
Median · Months
PFS Per RECIST v1.1 in the PD-L1 CPS ≥1 Population
MonthsFeladilimab + Pembrolizumab + 5-FU-platinum ChemotherapyPlacebo + Pembrolizumab + 5-FU-platinum Chemotherapy
PFS Per RECIST v1.1 in the PD-L1 CPS ≥1 Population5.5 (3.7 to 5.5)4.7 (4.7 to 6.1)
Statistical analysis
  • Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy vs Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy · Stratified Cox proportional hazard model · p = 0.284 (Nominal p-value was calculated based on the one sided log-rank test, stratified by stratified by PD-L1 expression (CPS ≥20 vs. 1≤ CPS \<20) and HPV status (oropharynx HPV positive vs oropharynx HPV negative/unknown and non-oropharynx).) · Hazard ratio (hr): 0.70 · 95% CI 0.20 to 2.43
SecondaryMilestone OS Rate at 12, 24 and 36 Months in mITT Population

Milestone OS rate at 12, 24, and 36 months was not evaluated.

Time frame:
Months 12, 24 and 36

No measurements were reported for this outcome.

SecondaryMilestone OS Rate at 12, 24 and 36 Months in PD-L1 CPS ≥1 Population

Milestone OS rate at 12, 24, and 36 months was not evaluated. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

Time frame:
Months 12, 24 and 36

No measurements were reported for this outcome.

SecondaryOverall Response Rate (ORR) Per RECIST v1.1 in mITT Population

ORR per RECIST v1.1 was defined as the proportion of the participants who have a complete response (CR) or partial response (PR) as the best overall response per RECIST v1.1 based upon investigator assessment. As a randomized double-blind study in which primary endpoints are OS and PFS, the confirmation of CR and PR was not required. Rate and associated 2-sided 95 percent Exact (Clopper-Pearson) Confidence Intervals are provided for each treatment arm which are unadjusted.

Time frame:
Up to approximately 7 months
Reported as:
Number · Percentage of participants
Overall Response Rate (ORR) Per RECIST v1.1 in mITT Population
Percentage of participantsFeladilimab + Pembrolizumab + 5-FU-platinum ChemotherapyPlacebo + Pembrolizumab + 5-FU-platinum Chemotherapy
Overall Response Rate (ORR) Per RECIST v1.1 in mITT Population19.2 (9.6 to 32.5)23.6 (13.2 to 37.0)
Statistical analysis
  • Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy vs Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy · Difference in percentage: -4.8 · 95% CI -20.8 to 11.3
SecondaryORR Per RECIST v1.1 in PD-L1 CPS ≥1 Population

ORR per RECIST v1.1 was defined as the proportion of the participants who have a complete response (CR) or partial response (PR) as the best overall response per RECIST v1.1 based upon investigator assessment. As a randomized double-blind study in which primary endpoints are OS and PFS, the confirmation of CR and PR was not required. Rate and associated 2-sided 95 percent Exact (Clopper-Pearson) Confidence Intervals are provided for each treatment arm which are unadjusted. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

Time frame:
Up to approximately 7 months
Reported as:
Number · Percentage of participants
ORR Per RECIST v1.1 in PD-L1 CPS ≥1 Population
Percentage of participantsFeladilimab + Pembrolizumab + 5-FU-platinum ChemotherapyPlacebo + Pembrolizumab + 5-FU-platinum Chemotherapy
ORR Per RECIST v1.1 in PD-L1 CPS ≥1 Population18.4 (8.8 to 32.0)23.1 (12.5 to 36.8)
Statistical analysis
  • Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy vs Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy · Difference in percentage: -5.1 · 95% CI -21.4 to 11.3
SecondaryDisease Control Rate (DCR) Per RECIST v1.1 in mITT Population

DCR per RECIST v1.1 based upon investigator assessment, was defined as the percentage of participants with a best overall response of CR or PR at any time plus stable disease (SD) meeting the minimum time of 15 weeks. A status of SD≥15 weeks will be assigned if the follow-up disease assessment has met the SD criteria at least once after the date of randomization at a minimum of 14 weeks (98 days) considering a one-week visit window. Rate and associated 2-sided 95 percent Exact (Clopper-Pearson) Confidence Intervals are provided for each treatment arm which are unadjusted.

Time frame:
Up to approximately 7 months
Reported as:
Number · Percentage of participants
Disease Control Rate (DCR) Per RECIST v1.1 in mITT Population
Percentage of participantsFeladilimab + Pembrolizumab + 5-FU-platinum ChemotherapyPlacebo + Pembrolizumab + 5-FU-platinum Chemotherapy
Disease Control Rate (DCR) Per RECIST v1.1 in mITT Population32.7 (20.3 to 47.1)36.4 (23.8 to 50.4)
Statistical analysis
  • Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy vs Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy · Difference in percentage: -4.8 · 95% CI -22.2 to 13.1
SecondaryDCR Per RECIST v1.1 in PD-L1 CPS ≥1 Population

DCR per RECIST v1.1 based upon investigator assessment, was defined as the percentage of participants with a best overall response of CR or PR at any time plus stable disease (SD) meeting the minimum time of 15 weeks. A status of SD≥15 weeks will be assigned if the follow-up disease assessment has met the SD criteria at least once after the date of randomization at a minimum of 14 weeks (98 days) considering a one-week visit window. Rate and associated 2-sided 95 percent Exact (Clopper-Pearson) Confidence Intervals are provided for each treatment arm which are unadjusted. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

Time frame:
Up to approximately 7 months
Reported as:
Number · Percentage of participants
DCR Per RECIST v1.1 in PD-L1 CPS ≥1 Population
Percentage of participantsFeladilimab + Pembrolizumab + 5-FU-platinum ChemotherapyPlacebo + Pembrolizumab + 5-FU-platinum Chemotherapy
DCR Per RECIST v1.1 in PD-L1 CPS ≥1 Population30.6 (18.3 to 45.4)34.6 (22.0 to 49.1)
Statistical analysis
  • Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy vs Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy · Difference in percentage: -5.1 · 95% CI -22.8 to 13.3
SecondaryDuration of Response (DoR) Per RECIST v1.1 in mITT Population

DoR per RECIST v1.1 is defined as the time from first documented evidence of CR or PR until first documented disease progression per RECIST v1.1 based upon investigator assessment or death due to any cause, whichever occurs first, among participants who demonstrated CR or PR as the best overall response per RECIST v1.1. Kaplan-Meier estimate for the median DoR is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.

Time frame:
Up to approximately 7 months
Reported as:
Median · Months
Duration of Response (DoR) Per RECIST v1.1 in mITT Population
MonthsFeladilimab + Pembrolizumab + 5-FU-platinum ChemotherapyPlacebo + Pembrolizumab + 5-FU-platinum Chemotherapy
Duration of Response (DoR) Per RECIST v1.1 in mITT PopulationNA (NA to NA)2.8 (1.2 to 2.8)
SecondaryDoR Per RECIST v1.1 in PD-L1 CPS ≥1 Population

DoR per RECIST v1.1 is defined as the time from first documented evidence of CR or PR until first documented disease progression per RECIST v1.1 based upon investigator assessment or death due to any cause, whichever occurs first, among participants who demonstrated CR or PR as the best overall response per RECIST v1.1. Kaplan-Meier estimate for the median DoR is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

Time frame:
Up to approximately 7 months
Reported as:
Median · Months
DoR Per RECIST v1.1 in PD-L1 CPS ≥1 Population
MonthsFeladilimab + Pembrolizumab + 5-FU-platinum ChemotherapyPlacebo + Pembrolizumab + 5-FU-platinum Chemotherapy
DoR Per RECIST v1.1 in PD-L1 CPS ≥1 PopulationNA (NA to NA)2.8 (1.4 to 2.8)
SecondaryNumber of Participants With Adverse Events (AEs) in Safety Population

An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention

Time frame:
Up to approximately 37.2 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events (AEs) in Safety Population
ParticipantsFeladilimab + Pembrolizumab + 5-FU-platinum ChemotherapyPlacebo + Pembrolizumab + 5-FU-platinum Chemotherapy
Number of Participants With Adverse Events (AEs) in Safety Population5165
SecondaryNumber of Participants With Serious Adverse Events (SAEs) in Safety Population

SAE was defined as any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect and other situations according to medical or scientific judgement.

Time frame:
Up to approximately 37.2 months
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs) in Safety Population
ParticipantsFeladilimab + Pembrolizumab + 5-FU-platinum ChemotherapyPlacebo + Pembrolizumab + 5-FU-platinum Chemotherapy
Number of Participants With Serious Adverse Events (SAEs) in Safety Population2332
SecondaryNumber of Participants With Adverse Events of Special Interest (AESI) in Safety Population

AESI were defined as events of potential immunologic etiology, including immune-related AEs (irAEs).

Time frame:
Up to approximately 37.2 months
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events of Special Interest (AESI) in Safety Population
ParticipantsFeladilimab + Pembrolizumab + 5-FU-platinum ChemotherapyPlacebo + Pembrolizumab + 5-FU-platinum Chemotherapy
Number of Participants With Adverse Events of Special Interest (AESI) in Safety Population2943
SecondaryNumber of Participants With AEs in Programmed Death Ligand-1 (PD-L1) Combined Positive Score (CPS ≥1) Population

Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

Time frame:
Up to approximately 37.2 months
Reported as:
Count of participants · Participants
Number of Participants With AEs in Programmed Death Ligand-1 (PD-L1) Combined Positive Score (CPS ≥1) Population
ParticipantsFeladilimab + Pembrolizumab + 5-FU-platinum ChemotherapyPlacebo + Pembrolizumab + 5-FU-platinum Chemotherapy
Number of Participants With AEs in Programmed Death Ligand-1 (PD-L1) Combined Positive Score (CPS ≥1) Population4862
SecondaryNumber of Participants With SAEs in PD-L1 CPS ≥1 Population

SAE was defined as any untoward medical occurrence that, at any dose, resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was a congenital anomaly/birth defect and other situations according to medical or scientific judgement. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

Time frame:
Up to approximately 37.2 months
Reported as:
Count of participants · Participants
Number of Participants With SAEs in PD-L1 CPS ≥1 Population
ParticipantsFeladilimab + Pembrolizumab + 5-FU-platinum ChemotherapyPlacebo + Pembrolizumab + 5-FU-platinum Chemotherapy
Number of Participants With SAEs in PD-L1 CPS ≥1 Population2132
SecondaryNumber of Participants With AESIs in PD-L1 CPS ≥1 Population

AESI were defined as events of potential immunologic etiology, including immune-related AEs (irAEs). CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

Time frame:
Up to approximately 37.2 months
Reported as:
Count of participants · Participants
Number of Participants With AESIs in PD-L1 CPS ≥1 Population
ParticipantsFeladilimab + Pembrolizumab + 5-FU-platinum ChemotherapyPlacebo + Pembrolizumab + 5-FU-platinum Chemotherapy
Number of Participants With AESIs in PD-L1 CPS ≥1 Population2740
SecondarySeverity of AEs in Safety Population

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Severity for each AE was reported during the study and assigned a grade according to the NCI-CTCAE v5.0. from Grade 1 through Grade 5. Grade 1= mild toxicity; Grade 2 = moderate toxicity; Grade 3 = severe toxicity; Grade 4 = life-threatening or disabling toxicity, Grade 5 = death related to toxicity.

Time frame:
Up to approximately 37.2 months
Reported as:
Count of participants · Participants
Severity of AEs in Safety Population
ParticipantsFeladilimab + Pembrolizumab + 5-FU-platinum ChemotherapyPlacebo + Pembrolizumab + 5-FU-platinum Chemotherapy
Grade 113
Grade 21715
Grade 32334
Grade 4410
Grade 563
SecondarySeverity of SAEs in Safety Population

A SAE was defined as any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, is a congenital anomaly/birth defect, any other situation such as important medical events according to medical or scientific judgement. Severity for each SAE was reported during the study and assigned a grade according to the NCI-CTCAE v5.0. from Grade 1 through Grade 5. Grade 1= mild toxicity; Grade 2 = moderate toxicity; Grade 3 = severe toxicity; Grade 4 = life-threatening or disabling toxicity, Grade 5 = death related to toxicity. Data of participants experiencing SAEs of Grade \>= 3 has been presented.

Time frame:
Up to approximately 37.2 months
Reported as:
Count of participants · Participants
Severity of SAEs in Safety Population
ParticipantsFeladilimab + Pembrolizumab + 5-FU-platinum ChemotherapyPlacebo + Pembrolizumab + 5-FU-platinum Chemotherapy
Severity of SAEs in Safety Population1726
SecondarySeverity of AESIs in Safety Population

AESI were defined as events of potential immunologic etiology, including immune-related AEs (irAEs). Severity of each AESI was reported during the study and was assigned a grade according to the NCI-CTCAE. AESIs severity were graded on a 5-point scale as: 1 = mild; discomfort noticed, but no disruption to daily activity, 2 = moderate; discomfort sufficient to reduce or affect normal daily activity, 3 = severe; inability to work or perform normal daily activity, 4 = life-threatening consequences and 5 = death related to AE. Data of participants experiencing AESIs of Grade \>= 3 have been presented.

Time frame:
Up to approximately 37.2 months
Reported as:
Count of participants · Participants
Severity of AESIs in Safety Population
ParticipantsFeladilimab + Pembrolizumab + 5-FU-platinum ChemotherapyPlacebo + Pembrolizumab + 5-FU-platinum Chemotherapy
Severity of AESIs in Safety Population54
SecondarySeverity of AEs in PD-L1 CPS ≥1 Population

An AE was defined as any untoward medical occurrence in a clinical study participant, temporally associated with the use of a study intervention, whether or not considered related to the study intervention. Severity for each AE was reported during the study and assigned a grade according to the NCI-CTCAE v5.0. from Grade 1 through Grade 5. Grade 1= mild toxicity; Grade 2 = moderate toxicity; Grade 3 = severe toxicity; Grade 4 = life-threatening or disabling toxicity, Grade 5 = death related to toxicity. Data of participants experiencing AEs of Grade \>= 3 have been presented. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

Time frame:
Up to approximately 37.2 months
Reported as:
Count of participants · Participants
Severity of AEs in PD-L1 CPS ≥1 Population
ParticipantsFeladilimab + Pembrolizumab + 5-FU-platinum ChemotherapyPlacebo + Pembrolizumab + 5-FU-platinum Chemotherapy
Severity of AEs in PD-L1 CPS ≥1 Population3045
SecondarySeverity of SAEs in PD-L1 CPS ≥1 Population

A SAE was defined as any untoward medical occurrence that, at any dose resulted in death, was life-threatening, required inpatient hospitalization or prolongation of existing hospitalization, resulted in persistent disability/incapacity, is a congenital anomaly/birth defect, any other situation such as important medical events according to medical or scientific judgement. Severity for each SAE was reported during the study and assigned a grade according to the NCI-CTCAE v5.0. from Grade 1 through Grade 5. Grade 1= mild toxicity; Grade 2 = moderate toxicity; Grade 3 = severe toxicity; Grade 4 = life-threatening or disabling toxicity, Grade 5 = death related to toxicity. Data of participants that experienced SAEs of Grade \>= 3 have been presented. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

Time frame:
Up to approximately 37.2 months
Reported as:
Count of participants · Participants
Severity of SAEs in PD-L1 CPS ≥1 Population
ParticipantsFeladilimab + Pembrolizumab + 5-FU-platinum ChemotherapyPlacebo + Pembrolizumab + 5-FU-platinum Chemotherapy
Severity of SAEs in PD-L1 CPS ≥1 Population1526
SecondarySeverity of AESI in PD-L1 CPS ≥1 Population

AESI were defined as events of potential immunologic etiology, including immune-related AEs (irAEs). Severity of each AESI was reported during the study and was assigned a grade according to the NCI-CTCAE. AESIs severity were graded on a 5-point scale as: 1 = mild; discomfort noticed, but no disruption to daily activity, 2 = moderate; discomfort sufficient to reduce or affect normal daily activity, 3 = severe; inability to work or perform normal daily activity, 4 = life-threatening consequences and 5 = death related to AE. Data of participants that experienced AESIs of Grade \>= 3 have been presented.

Time frame:
Up to approximately 37.2 months
Reported as:
Count of participants · Participants
Severity of AESI in PD-L1 CPS ≥1 Population
ParticipantsFeladilimab + Pembrolizumab + 5-FU-platinum ChemotherapyPlacebo + Pembrolizumab + 5-FU-platinum Chemotherapy
Severity of AESI in PD-L1 CPS ≥1 Population54
SecondaryNumber of Participants With Dose Modifications in Safety Population

Number of participants with dose modifications (including dose interruptions, dose delays, dose reductions and treatment discontinuations) were reported by each interventional component.

Time frame:
Up to approximately 7 months
Reported as:
Count of participants · Participants
Number of Participants With Dose Modifications in Safety Population
ParticipantsFeladilimab + Pembrolizumab + 5-FU-platinum ChemotherapyPlacebo + Pembrolizumab + 5-FU-platinum Chemotherapy
Dose interruption per component - feladilimab0NA
Dose interruption per component - placeboNA0
Dose interruption per component - pembrolizumab00
Dose interruption per component - carboplatin/cisplatin11
Dose interruption per component - fuorouracil07
Dose delays per component - feladilimab13NA
Dose delays per component - placeboNA12
Dose delays per component - pembrolizumab1313
Dose delays per component - cisplatin/carboplatin129
Dose delays per component - fluorouracil910
Dose Reduction per component - feladilimabNANA
Dose Reduction per component - placeboNANA
Dose Reduction per component - pembrolizumabNANA
Dose Reduction per component - carboplatin/cisplatin1219
Dose Reduction per component - fluorouracil1821
Treatment discontinuation per component - feladilimab/placebo5056
Treatment discontinuation per component - pembrolizumab1015
Treatment discontinuation per component - carboplatin/cisplatin1618
Treatment discontinuation per component - fluorouracil1318
SecondaryNumber of Participants With Dose Modifications in PD-L1 CPS ≥1 Population

Number of participants with dose modifications (including dose interruptions, dose delays, dose reductions and treatment discontinuations) were reported by each interventional component. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells.

Time frame:
Up to approximately 7 months
Reported as:
Count of participants · Participants
Number of Participants With Dose Modifications in PD-L1 CPS ≥1 Population
ParticipantsFeladilimab + Pembrolizumab + 5-FU-platinum ChemotherapyPlacebo + Pembrolizumab + 5-FU-platinum Chemotherapy
Dose Interruptions per component- feladilimab0NA
Dose Interruptions per component- placeboNA0
Dose Interruptions per component- pembrolizumab00
Dose Interruptions per component- carboplatin/cisplatin11
Dose Interruptions per component- fluorouracil07
Dose Delays per component - feladilimab12NA
Dose Delays per component - placeboNA11
Dose Delays per component - pembrolizumab212
Dose Delays per component - carboplatin/cisplatin119
Dose Delays per component - fluorouracil89
Dose Reductions per component - feladilimabNANA
Dose Reductions per component - placeboNANA
Dose Reductions per component - pembrolizumabNANA
Dose Reductions per component - carboplatin/cisplatin1116
Dose Reductions per component - fluorouracil1619
Treatment Discontinuations per component - feladilimab/placebo4753
Treatment Discontinuations per component - pembrolizumab1014
Treatment Discontinuations per component - carboplatin/cisplatin1316
Treatment Discontinuations per component - fluorouracil1516
SecondaryTime to Deterioration (TTD) in Pain in mITT Population

TTD in pain is defined as the time from randomization to the first definitive meaningful deterioration from baseline in the European Organization for Research and Treatment of Cancer Item Library(EORTC IL51) Questionnaire pain domain, i.e. an increase from baseline of at least 8.33 observed at all subsequent non-missing visits. The EORTC Quality of Life Questionnaire 35-Item Head and Neck Module (QLQ-H\&N35) is a head and neck specific module with multi-item scales. The mouth pain, swallowing, speech problems, opening mouth, coughing, feeding tube, and trouble with social eating domains were administered and referred to as the EORTC IL51. The questionnaire scores for each scale and single-item measure are averaged and transformed linearly to present a score ranging from 0-100. A high score represents a high/healthy level of functioning. Kaplan-Meier estimate for the median TTD is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method.

Time frame:
Up to approximately 7 months
Reported as:
Median · Months
Time to Deterioration (TTD) in Pain in mITT Population
MonthsFeladilimab + Pembrolizumab + 5-FU-platinum ChemotherapyPlacebo + Pembrolizumab + 5-FU-platinum Chemotherapy
Time to Deterioration (TTD) in Pain in mITT Population4.4 (2.1 to 4.4)2.8 (1.4 to NA)
Statistical analysis
  • Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy vs Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy · Stratified Cox proportional hazard model · p = 0.329 (Nominal p-value was calculated based on the one sided log-rank test, stratified by stratified by PD-L1 expression (CPS ≥20 vs. 1≤ CPS \<20 vs. CPS \<1) and HPV status (oropharynx HPV positive vs oropharynx HPV negative/unknown and non-oropharynx).) · Hazard ratio (hr): 0.85 · 95% CI 0.42 to 1.71
SecondaryTTD in Pain in PD-L1 CPS ≥1 Population

TTD in pain is defined as the time from randomization to the first definitive meaningful deterioration from baseline in the EORTC IL51 pain domain, i.e. an increase from baseline of at least 8.33 observed at all subsequent non-missing visits. The EORTC QLQ-H\&N35 is a head and neck specific module with multi-item scales. The mouth pain, swallowing, speech problems, opening mouth, coughing, feeding tube, and trouble with social eating domains were administered and referred to as the EORTC IL51. The questionnaire scores for each scale and single-item measure are averaged and transformed linearly to present a score ranging from 0-100. A high score represents a high/healthy level of functioning. Kaplan-Meier estimate for the median TTD is presented, along with associated 95% confidence interval, estimated using the Brookmeyer-Crowley method. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells to the total number of viable tumor cells.

Time frame:
Up to approximately 7 months
Reported as:
Median · Months
TTD in Pain in PD-L1 CPS ≥1 Population
MonthsFeladilimab + Pembrolizumab + 5-FU-platinum ChemotherapyPlacebo + Pembrolizumab + 5-FU-platinum Chemotherapy
TTD in Pain in PD-L1 CPS ≥1 Population3.4 (1.3 to 4.4)2.8 (1.4 to NA)
Statistical analysis
  • Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy vs Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy · Stratified Cox proportional hazard model · p = 0.302 (Nominal p-value was calculated based on the one sided log-rank test, stratified by stratified by PD-L1 expression (CPS ≥20 vs. 1≤ CPS \<20) and HPV status (oropharynx HPV positive vs oropharynx HPV negative/unknown and non-oropharynx).) · Hazard ratio (hr): 0.82 · 95% CI 0.40 to 1.69
SecondaryTTD in Physical Function in mITT Population

TTD in physical function (PF) is defined as the time from randomization to the first definitive meaningful deterioration from baseline in the PF T-score, i.e. a decrease from baseline of at least 2.4 observed at all subsequent non-missing visits, as measured by the Patient-Reported Outcomes Measurement Information System - Physical Function (PROMIS PF 8c).The PROMIS PF 8c is an 8-item fixed length short form derived from the PROMIS Physical Function item bank. It includes a 5-point scale with three sets of response options. Scores on the PROMIS PF 8c are reported on a T score metric (mean = 50 and SD = 10), with higher scores reflecting better physical functioning.

Time frame:
Up to approximately 7 months
Reported as:
Median · Months
TTD in Physical Function in mITT Population
MonthsFeladilimab + Pembrolizumab + 5-FU-platinum ChemotherapyPlacebo + Pembrolizumab + 5-FU-platinum Chemotherapy
TTD in Physical Function in mITT Population2.8 (1.4 to NA)4.3 (2.1 to 5.6)
Statistical analysis
  • Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy vs Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy · Stratified Cox proportional hazard model · p = 0.472 (Nominal p-value was calculated based on the one sided log-rank test, stratified by stratified by PD-L1 expression (CPS ≥20 vs. 1≤ CPS \<20 vs. CPS \<1) and HPV status (oropharynx HPV positive vs oropharynx HPV negative/unknown and non-oropharynx).) · Hazard ratio (hr): 0.96 · 95% CI 0.44 to 2.11
SecondaryTTD in Physical Function in PD-L1 CPS ≥1 Population

TTD in PF is defined as the time from randomization to the first definitive meaningful deterioration from baseline in the PF T-score, i.e. a decrease from baseline of at least 2.4 observed at all subsequent non-missing visits, as measured by the PROMIS PF 8c.The PROMIS PF 8c is an 8-item fixed length short form derived from the PROMIS Physical Function item bank. It includes a 5-point scale with three sets of response options. Scores on the PROMIS PF 8c are reported on a T score metric (mean = 50 and SD = 10), with higher scores reflecting better physical functioning. CPS was defined as the ratio of the combined number of PD-L1 expressing tumor cells and immune cells (lymphocytes and macrophages) to the total number of viable tumor cells

Time frame:
Up to approximately 7 months
Reported as:
Median · Months
TTD in Physical Function in PD-L1 CPS ≥1 Population
MonthsFeladilimab + Pembrolizumab + 5-FU-platinum ChemotherapyPlacebo + Pembrolizumab + 5-FU-platinum Chemotherapy
TTD in Physical Function in PD-L1 CPS ≥1 Population4.8 (2.1 to NA)4.3 (2.1 to 5.6)
Statistical analysis
  • Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy vs Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy · Stratified Cox proportional hazard model · p = 0.335 (Nominal p-value was calculated based on the one sided log-rank test, stratified by stratified by PD-L1 expression (CPS ≥20 vs. 1≤ CPS \<20) and HPV status (oropharynx HPV positive vs oropharynx HPV negative/unknown and non-oropharynx).) · Hazard ratio (hr): 0.83 · 95% CI 0.36 to 1.90

Adverse events

Collected over All cause mortality, non-SAEs and SAEs were collected from Day 1 to up to approximately 37.2 months.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Feladilimab + Pembrolizumab + 5-FU-platinum Chemotherapy33/51 (64.7%)23/51 (45.1%)50/51 (98%)
Placebo + Pembrolizumab + 5-FU-platinum Chemotherapy39/65 (60%)32/65 (49.2%)63/65 (96.9%)
Most frequent serious events
Showing 10 of 76
Most frequent serious events
EventFeladilimab + Pembrolizumab + 5-FU-platinum ChemotherapyPlacebo + Pembrolizumab + 5-FU-platinum Chemotherapy
PneumoniaInfections and infestations2/515/65
Pneumonia aspirationInfections and infestations1/513/65
PyrexiaGeneral disorders2/512/65
COVID-19Infections and infestations2/511/65
Acute kidney injuryRenal and urinary disorders2/511/65
AnaemiaBlood and lymphatic system disorders1/512/65
Febrile neutropeniaBlood and lymphatic system disorders0/512/65
Acute myocardial infarctionCardiac disorders0/512/65
DiarrhoeaGastrointestinal disorders1/512/65
NauseaGastrointestinal disorders1/512/65
Most frequent other events
Showing 10 of 51
Most frequent other events
EventFeladilimab + Pembrolizumab + 5-FU-platinum ChemotherapyPlacebo + Pembrolizumab + 5-FU-platinum Chemotherapy
AnaemiaBlood and lymphatic system disorders27/5130/65
NauseaGastrointestinal disorders22/5132/65
FatigueGeneral disorders17/5124/65
NeutropeniaBlood and lymphatic system disorders9/5121/65
DiarrhoeaGastrointestinal disorders10/5121/65
ThrombocytopeniaBlood and lymphatic system disorders6/5117/65
ConstipationGastrointestinal disorders13/5116/65
StomatitisGastrointestinal disorders12/5116/65
Mucosal inflammationGeneral disorders6/5116/65
VomitingGastrointestinal disorders8/5113/65

Baseline characteristics

Age, Customized
Age, Customized(Participants)Feladilimab + Pembrolizumab + 5-FU-platinum ChemotherapyPlacebo + Pembrolizumab + 5-FU-platinum ChemotherapyTotal
18-64 years374077
>=65-84 years202040
Sex: Female, Male
Sex: Female, Male(Participants)Feladilimab + Pembrolizumab + 5-FU-platinum ChemotherapyPlacebo + Pembrolizumab + 5-FU-platinum ChemotherapyTotal
Female101424
Male474693
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Feladilimab + Pembrolizumab + 5-FU-platinum ChemotherapyPlacebo + Pembrolizumab + 5-FU-platinum ChemotherapyTotal
Asian - Central/South Asian Heritage213
Asian - East Asian Heritage5712
Asian - Japanese Heritage202
Asian - South East Asian Heritage213
Black or African American101
Missing213
White - White/Caucasian/European Heritage435093
09

Study locations

71 sites
  • GSK Investigational Site
    Duarte, California 91010, United States
  • GSK Investigational Site
    Buenos Aires, 1012, Argentina
  • GSK Investigational Site
    Ciudad AutOnoma de Buenos Aires, C1426ABP, Argentina
  • GSK Investigational Site
    Oro Verde Entre RIos, E3100XAD, Argentina
  • GSK Investigational Site
    Rosario, S2000DBS, Argentina
  • GSK Investigational Site
    San Miguel de TucumAn, T4000, Argentina
  • GSK Investigational Site
    Blacktown, 2148, Australia
  • GSK Investigational Site
    Heidelberg, 3084, Australia
  • GSK Investigational Site
    Melbourne, 3000, Australia
  • GSK Investigational Site
    Woolangabba, 4102, Australia
  • GSK Investigational Site
    Bruxelles, 1070, Belgium
  • GSK Investigational Site
    Edegem, 2650, Belgium
  • GSK Investigational Site
    Curitiba, 81520-060, Brazil
  • GSK Investigational Site
    SAo Paulo, 01246-000, Brazil
  • GSK Investigational Site
    VitOria, 29043-260, Brazil
  • GSK Investigational Site
    Edmonton, Alberta T6G 1Z2, Canada
  • GSK Investigational Site
    Hamilton, Ontario L8V 5C2, Canada
  • GSK Investigational Site
    London, Ontario N6A 4G5, Canada
  • GSK Investigational Site
    Toronto, Ontario M4N 3M5, Canada
  • GSK Investigational Site
    Toronto, Ontario M5G 2M9, Canada
  • GSK Investigational Site
    Montreal, Quebec H2X 3E4, Canada
  • GSK Investigational Site
    Koebenhavn, 2100, Denmark
  • GSK Investigational Site
    Bordeaux, 33000, France
  • GSK Investigational Site
    Lyon cedex 08, 69373, France
  • GSK Investigational Site
    Paris, 75005, France
  • GSK Investigational Site
    Poitiers, 86021, France
  • GSK Investigational Site
    Strasbourg, 67200, France
  • GSK Investigational Site
    Berlin, 12203, Germany
  • GSK Investigational Site
    Hannover, 30625, Germany
  • GSK Investigational Site
    Leipzig, 04103, Germany
  • GSK Investigational Site
    Ulm, 89075, Germany
  • GSK Investigational Site
    Dublin, 8, Ireland
  • GSK Investigational Site
    Brescia, 25123, Italy
  • GSK Investigational Site
    Firenze, 59100, Italy
  • GSK Investigational Site
    Milano, 20132, Italy
  • GSK Investigational Site
    Napoli, 80131, Italy
  • GSK Investigational Site
    Roma, 00144, Italy
  • GSK Investigational Site
    Savona, 17100, Italy
  • GSK Investigational Site
    Osaka, 541-8567, Japan
  • GSK Investigational Site
    Osaka, 589-8511, Japan
  • GSK Investigational Site
    Tokyo, 104-0045, Japan
  • GSK Investigational Site
    Tokyo, 135-8550, Japan
  • GSK Investigational Site
    Daegu, 42601, Korea, Republic of
  • GSK Investigational Site
    Gyeonggi-do, 10408, Korea, Republic of
  • GSK Investigational Site
    Hwasun, 58128, Korea, Republic of
  • GSK Investigational Site
    Incheon, 21565, Korea, Republic of
  • GSK Investigational Site
    Seoul, 05505, Korea, Republic of
  • GSK Investigational Site
    Seoul, 137-701, Korea, Republic of
  • GSK Investigational Site
    Bydgoszcz, 85-796, Poland
  • GSK Investigational Site
    Gdynia, 81-519, Poland
  • GSK Investigational Site
    Gliwice, 44-102, Poland
  • GSK Investigational Site
    Lublin, 20-090, Poland
  • GSK Investigational Site
    Tomaszow Mazowiecki, 97-200, Poland
  • GSK Investigational Site
    Warszawa, 02-781, Poland
  • GSK Investigational Site
    Bucuresti, 021389, Romania
  • GSK Investigational Site
    Cluj Napoca, 400015, Romania
  • GSK Investigational Site
    Craiova, 200347, Romania
  • GSK Investigational Site
    Floresti, 407280, Romania
  • GSK Investigational Site
    Otopeni, 075100, Romania
  • GSK Investigational Site
    Suceava, 720284, Romania
  • GSK Investigational Site
    Pushkin, 196603, Russian Federation
  • GSK Investigational Site
    Barcelona, 08035, Spain
  • GSK Investigational Site
    Madrid, 28040, Spain
  • GSK Investigational Site
    Madrid, 28041, Spain
  • GSK Investigational Site
    Madrid, 28046, Spain
  • GSK Investigational Site
    Madrid, 28050, Spain
  • GSK Investigational Site
    Valencia, 46026, Spain
  • GSK Investigational Site
    Stockholm, SE-171 64, Sweden
  • GSK Investigational Site
    London, SW3 6JJ, United Kingdom
  • GSK Investigational Site
    Nottingham, NG5 1PB, United Kingdom
  • GSK Investigational Site
    Sutton, SM2 5PT, United Kingdom
10

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — IPD for this study will be made available via the Clinical Study Data Request site.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · clinicalstudydatarequest.com

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2020 to primary completion in Apr 2021, 8 months.

Results were first posted in May 2022, 1 year after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2020
First posted
Jun 11, 2020
StartActual
Aug 12, 2020
Primary completionActual
Apr 27, 2021
CompletionActual
Sep 19, 2023
Results first posted
May 25, 2022
Last update
Oct 9, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT04428333
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
Jun 11, 2020
Start date
Aug 12, 2020
Primary completion
Apr 27, 2021
Completion
Sep 19, 2023
Results posted
May 25, 2022
Last update
Oct 9, 2024

Study contacts

GSK Clinical Trials
study director · GlaxoSmithKline

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Feladilimab

Start the discussion